“Shadow Lord” picks up one year after the Clone Wars, following the activation of Order 66 and the Empire’s occupation across the galaxy. The story takes place on Janix, a gray-paletted, ...

To mark the first solar eclipse of 2026, Google has launched a special ‘Ring of Fire’ interactive animation on its search page. This feature allows people across the world to experience the annular ...

We’re still in the earliest days of artificial intelligence. It was just November 2022 when OpenAI released ChatGPT, and the world changed. However, enough time has passed for us to have a sufficient ...

Microsoft has released the KB5074105 preview cumulative update for Windows 11 systems, which includes 32 changes, including fixes for sign-in, boot, and activation issues. KB5074105 is an optional ...

This is read by an automated voice. Please report any issues or inconsistencies here. Animation is the backbone of the film industry, boosting the global box office year after year. But such ...

PCWorld reports that Microsoft has quietly discontinued telephone activation for Windows 10 and 11, eliminating the last method to activate Windows without an internet connection. Users calling the ...

In a human organoid-based mechanistic investigation, researchers revealed how an immunosuppressive drug, antithymocyte globulin (ATG), induces injury to blood vessels in the liver. According to the ...

Runners know they’re supposed to do more than just run. Strength training makes you stronger so you can run harder and longer. Mobility exercises make you run more efficiently. Postrun stretching can ...

EXCLUSIVE: L.A. publisher Gungnir is launching an animation studio that will feed an in-house YouTube channel that planned as “the Cartoon Network of the digital era.” Gungnir Animation Studio will ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...